Electrosprayed chitosan/alginate/polyvinyl alcohol nanoparticles as boric acid carriers for 10Boron neutron capture therapy

Aim: To improve the killing efficacy of head and neck squamous cells (SAS) by boric acid-mediated boron neutron capture therapy (BNCT). Materials & methods: Boric acid-containing chitosan/alginate/polyvinyl alcohol nanoparticles (B-capNPs) were manufactured using the nano-electrospray process. R...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine (London, England) England), 2020-05, Vol.15 (11), p.1067-1077
Main Authors: Wu, Wei-Cheng, Wang, Shao-Hua, Ou, Shu-Ting, Liu, Yen-Wan Hsueh, Liu, Bo-Heng, Tseng, Fan-Gang
Format: Article
Language:English
Subjects:
Acids
Atoms & subatomic particles
Boron
Cancer therapies
Chemical reactions
Drugs
Efficiency
Molecular weight
Nanoparticles
Polyvinyl alcohol
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim: To improve the killing efficacy of head and neck squamous cells (SAS) by boric acid-mediated boron neutron capture therapy (BNCT). Materials & methods: Boric acid-containing chitosan/alginate/polyvinyl alcohol nanoparticles (B-capNPs) were manufactured using the nano-electrospray process. Results: Less than 10% of the boric acid leaked from the B-capNPs over 2 days. The B-capNPs killed up to 2.8-fold more SAS cells and reduced cytotoxicity tenfold when compared with pure boric acid alone. B-capNPs show selective uptake in tumor cells with tumor/normal ratios of SAS to normal (NIH 3T3) and macrophage (RAW 264.7) cells of 4.0 and 3.5, respectively, which are greater than the minimum acceptable tumor/normal ratio for BNCT of 2.5. Conclusion: These findings illustrate that B-capNPs may be more superior as BNCT drugs than pure boric acid.
ISSN:1743-5889
1748-6963
DOI:10.2217/nnm-2019-0465